OVARIAN CANCER and US: pathogenesis

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label pathogenesis. Show all posts
Showing posts with label pathogenesis. Show all posts

Tuesday, January 24, 2012

abstract - Current Obstetrics and Gynecology Reports: Ovarian Cancer is an Imported Disease: Fact or Fiction?



Abstract


The cell of origin of ovarian cancer has been long debated. The current paradigm is that epithelial ovarian cancer (EOC) arises from the ovarian surface epithelium (OSE). OSE is composed of flat, nondescript cells more closely resembling the mesothelium lining the peritoneal cavity. In light of various histologic types of ovarian carcinoma (serous, endometrioid, and clear cell carcinoma), which have a Müllerian phenotype, it has been argued that the OSE undergoes a process termed “metaplasia” to account for this profound morphologic transformation.

Recent molecular and clinicopathologic studies not only have failed to support this hypothesis but also have provided evidence that EOC stems from Müllerian-derived extraovarian cells that involve the ovary secondarily, thereby calling into question the very existence of primary EOC.

This new model of ovarian carcinogenesis proposes that fallopian tube epithelium (benign or malignant) implants on the ovary to give rise to both high-grade and low-grade serous carcinomas, and that endometrial tissue implants on the ovary and produces endometriosis, which can undergo malignant transformation into endometrioid and clear cell carcinoma.

Thus, ultimately EOC is not ovarian in origin but rather is secondary, and it is logical to conclude that the only true primary ovarian neoplasms are germ cell and gonadal stromal tumors analogous to tumors in the testis. If this new model is confirmed, it has profound implications for the early detection and treatment of “ovarian cancer”.
Keywords Ovarian cancer – Pathogenesis – Model – Paradigm – Fallopian tube – Endometriosis – Serous tubal intraepithelial carcinoma – STIC – Serous carcinoma

Saturday, May 28, 2011

Editorial - no abstract/pay-per-view: - Gynecologic Oncology : More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis



Abstract


Gynecologic Oncology
Volume 121, Issue 3, 1 June 2011, Pages 429-430

Editorial
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis
Robert C. Bast Jr.a, low asterisk, E-mail The Corresponding Author and David R. Spriggsb
a Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
b Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

Available online 19 May 2011.

References

Corresponding Author Contact InformationCorresponding author. Unit 1439, U.T. M.D. Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA. Fax: +1 713 792 7864.